Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.
EML status history
First added in 1999 (TRS 895) for Lymphoid leukaemia, not elsewhere classified
Added in 1999 (TRS 895) for Acute myeloid leukaemia with recurrent genetic abnormalities
Added in 1999 (TRS 895) for Myeloid leukaemia
- Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection